SPY763.28+0.09%QQQ740.64+0.12%BTC/USD83,704.81+0.09%DIA508.96+0.08%GLD381.00+0.04%TLT77.77−0.01%
Benzinga

Lifecore Biomedical Inc

LFCRNASDAQ
Trade with Public
Trade with Public
$6.58
-0.01-0.15%
At close: Sep 30, 5:00 PM EST
$6.58
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Lifecore Biomedical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lifecore Biomedical (LFCR).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

1Buy
2Hold
Consensus RatingBuy# Analysts3Avg. Consensus PT$8Upside to Avg. PT+21.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 29, 2026Barrington ResearchMichael PetuskyDowngradeOutperform→Market Perform—
Sep 28, 2026William BlairMax SmockDowngradeOutperform→Market Perform—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barrington Research Downgrades Lifecore Biomedical to Market Perform

Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Benzinga Newsdesk

PRO
William Blair Downgrades Lifecore Biomedical to Market Perform

William Blair analyst Max Smock downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.
Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.
Benzinga Newsdesk

PRO
Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Market Perform to Outperform and announces $5.5 price target.
Benzinga Newsdesk

Lifecore Stock Sinks As Delayed Launches Push Growth Further Out

Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed growth plans weighing on shares.
Vandana Singh

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved